Frontline Insights
Our Frontline Insights series of expert discussions dives into the critical aspects of type 1 diabetes, from early detection and intervention to the latest treatment advancements. Our esteemed panel of experts discuss the impact of early screening, the role of teplizumab therapy, and the importance of timely intervention in delaying disease progression and improving patient outcomes.
Ahead of the Curve: Early Interventions for Delaying Type 1 Diabetes
December 18th 2024Javier Morales, MD, FACP, FACE; David Robertson, MD; Andrea Stallings, PA, and Shira Eytan, MD, FACE, examine the comprehensive burden of Type 1 diabetes, from screening guidelines and disease staging to the critical importance of early intervention, emphasizing how delayed treatment in Stage 2 can lead to severe complications and diminished therapeutic opportunities.
Paving the Path to Prevention: Managing Early Treatments for T1D Progression
December 18th 2024Javier Morales, MD, FACP, FACE; Shira Eytan, MD, FACE; Bethany Kinsey, NP; Quentin Van Meter, MD, and David Robertson, MD, discuss the progression and management of Type 1 diabetes, from early screening protocols through disease stages and intervention timing, emphasizing the critical importance of vigilant monitoring and prompt treatment to prevent severe complications.
Proactive Intervention: Strategies for Slowing Type 1 Diabetes Progression
December 10th 2024Panelists discuss how early screening, timely intervention with teplizumab, and a proactive, multidisciplinary approach can significantly delay the progression of type 1 diabetes (T1D) and improve patient outcomes.
Taking Charge Early: Navigating Treatment Options to Delay T1D Progression
December 4th 2024Panelists discuss how early screening, timely intervention, and the use of teplizumab can improve outcomes for individuals with type 1 diabetes (T1D) by delaying disease progression and reducing complications like diabetic ketoacidosis.
